Whether ponatinib has been included in medical insurance and a comprehensive analysis of the latest reimbursement policy and self-payment situation

Ponatinib (Ponatinib) is an oral third-generation tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL), especially suitable for patients who are resistant to the first two generations of TKIs or who have the T315I mutation. Its mechanism of action is to inhibit the activity of BCR-ABL fusion protein kinase, thereby inhibiting the proliferation and survival of leukemia cells.

In the domestic market, ponatinib has been officially launched, but so far it has not been included in the domestic medical insurance catalog and there is no relevant reimbursement policy. If the patient needs to use ponatinib, it can only be purchased through formal overseas channels, and the cost must be borne by the patient, which is completely self-pay. Since it is not covered by medical insurance, patients should fully evaluate their financial affordability and the feasibility of the treatment plan when using it.

According to overseas market conditions, the price of each box of the original version of ponatinib in Hong Kong is about 1.7 around 10,000 yuan. The specifications are generally 30 tablets / boxes for daily oral use. At the same time, the Lao and Bangladeshi versions of generic drugs have also been launched, with prices of approximately 700 yuan and 1,000 yuan per box respectively. The drug ingredients are basically the same as the original drugs, and the price is more affordable, making it suitable for patients with higher financial burdens. However, when using overseas or generic drugs, you need to ensure that they come from regular sources and be used under the guidance of a doctor to ensure efficacy and safety.

Generally speaking, domestic medical insurance reimbursement for ponatinib is not yet feasible, and self-pay purchase is currently the only way. Overseas original drugs are more expensive, while generic drugs from Laos or Bangladesh provide more economical alternatives. When patients choose purchasing channels, they should take into account their condition, financial conditions and doctor's advice to ensure safe, standardized and rational use of medicines.

Reference materials:https://www.drugs.com/